The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss

American Journal of Case Reports

Volumn 15, Issue , 2014, Pages 152-154

  Bell, David S H ^a  

^a Department of Endocrinology Southside Endocrinology ^*  (United States)

Author keywords

Diabetes mellitus; Incretins; Sodium glucose transporter 2; Type 2

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN ASPART; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; BODY MASS; CASE REPORT; CATARACT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MALE; MIDDLE AGED; NECK CIRCUMFERENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYNEUROPATHY; RETINA MACULA EDEMA; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84898402096     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.890626     Document Type: Article

References (7)

1. Garber AJ, Abrahamson MJ, Barzilay JI et al, American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract, 2013; 19(2): 327-36
2. Bailey T: Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med, 2013: 126(9 Suppl.1): S10-20
3. DeFronzo RA, Hompesch M, Kasichayanula S et al: Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care, 2013; 36(10): 3169-76
4. Vouyiouklis M: Canagliflozin: Improving diabetes by making urine sweet. Cleve Clin J Med, 2013; 80(11): 683-87
5. Stenlöf K, Cefalu WT, Kim KA et al: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab, 2013; 15(4): 372-82
6. Mervoci A, Solis-Herrera C, Daniele G et al: Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest, 2014; 124(2): 509-14
7. Drucker DJ: Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes, 2013; 62(10): 3316-23